Show simple item record

dc.contributor.authorMargetts, CDE
dc.contributor.authorMorris, M
dc.contributor.authorAstuti, D
dc.contributor.authorGentle, DC
dc.contributor.authorCascon, A
dc.contributor.authorMcRonald, FE
dc.contributor.authorCatchpoole, D
dc.contributor.authorRobledo, M
dc.contributor.authorNeumann, HPH
dc.contributor.authorLatif, F
dc.contributor.authorMaher, ER
dc.date.accessioned2019-07-11T14:09:08Z
dc.date.available2019-07-11T14:09:08Z
dc.date.issued2008-09-01
dc.identifier.citationMargetts, C. D. E., Morris, M., Astuti, D., Gentle, D. C., Cascon, A., McRonald, F. E., Catchpoole, D., Robledo, M., Neumann, H. P. H., Latif, F. and Maher, E. R. (2008) Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma, Endocrine-Related Cancer, 15(3), pp. 777–786.en
dc.identifier.pmid18499731
dc.identifier.doi10.1677/ERC-08-0072en
dc.identifier.urihttp://hdl.handle.net/2436/622541
dc.description.abstractThe molecular genetics of inherited phaeochromocytoma have received considerable attention, but the somatic genetic and epigenetic events that characterise tumourigenesis in sporadic phaeochromocytomas are less well defined. Previously, we found considerable overlap between patterns of promoter region tumour suppressor gene (TSG) hypermethylation in two neural crest tumours, neuroblastoma and phaeochromocytoma. In order to identify candidate biomarkers; and epigenetically inactivated TSGs in phaeochromocytoma and neuroblastoma, we characterised changes in gene expression in three neuroblastoma cell lines after treatment with the demethylating agent 5-azacytidine. Promoter region methylation status was then determined for 28 genes that demonstrated increased expression after demethylation. Three genes HSP47, homeobox A9 (HOXA9) and opioid binding protein (OPCML) were methylated in > 10% of phaeochromocytomas (52, 17 and 12% respectively). Two of the genes, epithelial membrane protein 3 (EMP3) and HSP47, demonstrated significantly more frequent methylation in neuroblastoma than phaeochromocytoma. These findings extend epigenotype of phaeochromocytoma and identify candidate genes implicated in sporadic phaeochromocytoma tumourigenesis. © 2008 Society for Endocrinology.en
dc.description.sponsorshipCancer Research UK and the University of Birminghamen
dc.formatapplication/PDFen
dc.languageeng
dc.language.isoenen
dc.publisherBioscientificaen
dc.relation.urlhttps://erc.bioscientifica.com/view/journals/erc/15/3/777.xmlen
dc.subjectCell Line, Tumoren
dc.subjectNeural Cresten
dc.subjectHumansen
dc.subjectNeuroblastomaen
dc.subjectPheochromocytomaen
dc.subjectAdrenal Gland Neoplasmsen
dc.subjectOligonucleotide Array Sequence Analysisen
dc.subjectGene Expression Profilingen
dc.subjectSequence Analysis, DNAen
dc.subjectDNA Methylationen
dc.subjectEpigenesis, Geneticen
dc.subjectCpG Islandsen
dc.subjectGenes, Tumor Suppressoren
dc.subjectAdulten
dc.subjectPromoter Regions, Geneticen
dc.titleEvaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastomaen
dc.typeJournal articleen
dc.identifier.eissn1479-6821
dc.identifier.journalEndocrine-Related Canceren
dc.date.updated2019-06-24T15:34:48Z
dc.contributor.institutionDepartment of Medical and Molecular Genetics, Institute of Biomedical Research Cancer Research, UK.
pubs.place-of-publicationEngland
rioxxterms.funderEMBO and ESFen
rioxxterms.identifier.projectUOW110719MMen
rioxxterms.versionVoRen
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2019-07-11en
dc.source.volume15
dc.source.issue3
dc.source.beginpage777
dc.source.endpage786
dc.description.versionPublished version
refterms.dateFCD2019-07-11T14:08:58Z
refterms.versionFCDVoR
refterms.dateFOA2019-07-11T14:09:08Z


Files in this item

Thumbnail
Name:
Evaluation of a functional ...
Size:
180.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record